COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]
AstraZeneca
Press Releases – No new digest announcements identified
Bharat Biotech
Press Releases – No new digest announcements identified
BioCubaFarma – Cuba
Últimas Noticias – No new digest announcements identified
CanSinoBIO
News – [Website not responding at inquiry]
Clover Biopharmaceuticals – China
News
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development Feb 1, 2022
Curevac [Bayer Ag – Germany]
News – No new digest announcements identified
Gamaleya National Center
Latest News and Events –
Sputnik V vaccine granted full permanent approval in Russia
:: Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use around the world.
:: Sputnik V has been authorized in 71 countries with total population of over 4 billion people.
February 4, 2022
IMBCAMS, China
Home – Website not responding at inquiry
Janssen/JNJ
Press Releases
Feb 01, 2022 United States
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
Moderna
Press Releases
January 31, 2022
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
:: Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
:: SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
:: 807 million doses of Moderna’s COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
Novavax
Press Releases
New Zealand’s Medsafe Grants Provisional Approval for Novavax’ COVID-19 Vaccine
Feb 3, 2022
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
Jan 31, 2022
Pfizer
Recent Press Releases
02.04.2022
Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
02.01.2022
Pfizer Announces New Chief Development Officer
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced that William Pao, M.D., Ph.D., will join the Company as Executive Vice President and Chief Development Officer effective March 21, 2022. Dr. Pao will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla. He joins Pfizer from Roche, where he most recently served as the Head of Pharma Research and Early Development (pRED) and oversaw the discovery and early development of a portfolio of new molecular entities to treat diseases related to cancer, neuroscience, ophthalmology, rare diseases, immunology, infectious diseases, and rare blood disorders, across seven global sites. He was also a member of Roche’s Enlarged Corporate Executive Committee.
Dr. Pao succeeds Rod MacKenzie who recently announced his intent to retire after a 35-year career at Pfizer. Mr. MacKenzie has agreed to continue in his role until a seamless transition is completed…
Sanofi Pasteur
Press Releases – No new digest announcements identified
Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified
Sinopharm/WIBPBIBP
News – No new digest announcements identified
Sinovac
Press Releases – No new digest announcements identified
Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified
Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]
::::::
GSK
Press releases for media – No new digest announcements identified
Merck
News releases – No new digest announcements identified
Novartis
News – No new digest announcements identified
SK Biosciences
Press releases – No new digest announcements identified
Valneva
Press Releases
February 4, 2022
Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
January 31, 2022
Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate
vaccines and global health :: ethics and policy 